Cost Of Treatment-Related Adverse Events (TRAES) In Second-Line (2l) Advanced Hepatocellular Carcinoma (AHCC)- Match Adjusted Indirect Comparison (MAIC) Of Nivolumab And Regorafenib

Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.590
https://www.valueinhealthjournal.com/article/S1098-3015(17)30924-5/fulltext
Title : Cost Of Treatment-Related Adverse Events (TRAES) In Second-Line (2l) Advanced Hepatocellular Carcinoma (AHCC)- Match Adjusted Indirect Comparison (MAIC) Of Nivolumab And Regorafenib
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30924-5&doi=10.1016/j.jval.2017.08.590
First page : A502
Section Title : Health Care Treatment Studies
Open access? : No
Section Order : 560
Categories :
Tags :
Regions :
ViH Article Tags :